SectorWire
SearchRegister
MenuClose

Polymarket and Kalshi offer markets on US measles cases and medical events

Regulation2 min read

Summary

Polymarket and Kalshi offer prediction markets on US measles case totals in 2026, with Kalshi’s contract asking whether cases will exceed 6,000. Both platforms use Centers for Disease Control and Prevention figures to settle these markets. Health policy academics warned that people with non-public information could gain an advantage, although no misuse was reported in the measles market.

Polymarket and Kalshi offer prediction markets on the number of US measles cases in 2026, with one Kalshi contract asking whether the total will exceed 6,000. Both platforms use figures from the Centers for Disease Control and Prevention (CDC) to determine the outcomes.

Kalshi's rules for the measles contract prohibit trading by employees of the agencies involved and people holding material non-public information about the outcome. The experts' warnings do not mean that misuse has been established in that market.

The platforms reportedly offer markets on vaccination advice, medical research results and drug approvals. Users can also bet on whether the US will lose its status as a country where measles has been eliminated.

Matthew Eisenberg, professor of health policy and management at the Johns Hopkins Bloomberg School of Public Health, said people with inside information could gain an advantage in markets on US Food and Drug Administration decisions or medical research results. Eisenberg said a financial interest in those markets could encourage information leaks. Lia Nower, professor and director of the Center for Gambling Studies at Rutgers University, said people with inside information or influence over an outcome could benefit.

Eisenberg said a single trader could substantially affect prices in small health markets. He said prices therefore do not automatically provide a reliable picture of public opinion or the expected outcome.

Request a correction

Flag an issue

Keep reading

Regulation

LeBron James sues PlayVision over AI advert using his identity

LeBron James filed a federal lawsuit in New York against PlayVision and its founders, alleging that a Bron betting-app advert used his nickname, image and synthetic voice without permission. James is seeking an injunction and damages; the founders said they removed the advert and would change the name, but the complaint says the app continued using Bron in its Apple listing.

LeBron James has sued PlayVision and its founders in a New York federal court, alleging that an advert for their Bron sports betting app used his nickname, image and a synthetic voice without permission. The defendants are PlayVision, which operates the app, and co-founders Anish Gupta and Marc Zoghby. James is seeking damages and a court order barring them from using his identity and the Bron name.

Continue reading